Cost-Effectiveness of Empagliflozin (Jardiance®) In The Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) In Turkey Based Empa-Reg Outcome Data

E Oksuz,B Urganci,E Kamaci,R Ersoy,A Temizhan,Y Balbay,E Tetik,S Malhan

doi:10.1016/j.jval.2017.08.457

Cost-Effectiveness of Empagliflozin (Jardiance®) In The Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) In Turkey Based Empa-Reg Outcome Data

E Oksuz, B Urganci + Show 6 more

Open Access

https://doi.org/10.1016/j.jval.2017.08.457

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Oct 1, 2017
Citations: 3	License type: publisher-specific-oa

Affiliation: Turkish Society of Hematology, Ankara Yıldırım Beyazıt University, Türkiye Yüksek İhtisas Hastanesi, Yüksek İhtisas Üniversitesi, Başkent University

#Cost-Effectiveness Of Empagliflozin #Type 2 Diabetes Mellitus + Show 3 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Cost-Effectiveness of Empagliflozin (Jardiance®) In The Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) In Turkey Based Empa-Reg Outcome Data

Full Text